Table 1 Characteristics of 13 trials meeting criteria for inclusion in the meta-analysis

Source	Design	Intervention	Duration of study	No of patients	Percentage of patients with hyperaemia			Jadad Score
Source	Design	Intervention	Duration of study	No of patients	LAT	BIMAT	TRAVO	Jadad Score
Gandolfi et al24	Parallel	LAT vs BIMAT	3 months	LAT = 113; BIMAT = 119	14.2	36.1		7
Dubiner et al25	Parallel	LAT vs BIMAT	1 month	LAT = 22; BIMAT = 21	13.6	14.3		5
Noecker et al26	Parallel	LAT vs BIMAT	6 months	LAT = 136; BIMAT = 133	20.6	44.4		7
Walters et al27	Parallel	LAT vs BIMAT	1 month	LAT = 38; BIMAT = 38	15.8	39.5		6
Konstas et al28	Crossover	LAT vs BIMAT	7 weeks each treatment	LAT = 21; BIMAT = 21	28.6	71.4		5
Dirks et al29	Parallel	LAT vs BIMAT	3 months	LAT = 27; BIMAT = 33	7.4	21.2		6
Konstas et al30	Crossover	LAT vs BIMAT	3 months each treatment	LAT = 123; BIMAT = 123	7.3	26		7
Netland et al31	Parallel	LAT vs TRAVO	12 months	LAT = 193; TRAVO = 402	27.6		44	6
Parrish et al32	Parallel	LAT vs TRAVO vs BIMAT	3 months	LAT = 136; BIMAT = 136; TRAVO = 138	47.1	68.6	58	7
Parmaksiz et al33	Parallel	LAT vs TRAVO	9 months	LAT = 16; TRAVO = 18	6.2		38.8	5
Chen et al34	Parallel	LAT vs TRAVO	3 months	LAT = 36; TRAVO = 37	8.3		13.5	6
Garcia-Feijoo et al35	Parallel	LAT vs TRAVO	2 weeks	LAT = 30; TRAVO = 32	3.3		6.2	5
Konstas et al36	Crossover	LAT vs TRAVO	8 weeks each treatment	LAT = 40; TRAVO = 40	15		37.5	6